Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease.

ABSTRACT:

Background

Currently available treatments for Alzheimer's disease (AD) can produce mild improvements in cognitive function, behavior, and activities of daily living in patients, but their influence on long-term survival is not well established. This study was designed to assess patient survival and drug efficacy following a 2-year galantamine treatment in patients with mild to moderately severe AD.

Methods

In this multicenter, double-blind study, patients were randomized 1:1 to receive galantamine or placebo. One primary end point was safety; mortality was assessed. An independent Data Safety Monitoring Board monitored mortality for the total deaths reaching prespecified numbers, using a time-to-event method and a Cox-regression model. The primary efficacy end point was cogn

SUBMITTER: Hager K 

PROVIDER: S-EPMC3937252 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature